Human medicines European public assessment report (EPAR): Livtencity, maribavir, Date of authorisation: 09/11/2022, Revision: 9, Status: Authorised

Evidence Dossier: Livtencity (maribavir) for Cytomegalovirus Infection in Transplant Patients What is Established Livtencity is an antiviral medication authorized for use in the European Union as of November 2022. Its active ingredient, maribavir, is indicated for the treatment of illness caused by cytomegalovirus (CMV) in adults who have undergone haematopoietic stem cell…

Human medicines European public assessment report (EPAR): Herwenda, trastuzumab, Date of authorisation: 15/11/2023, Revision: 4, Status: Authorised

FreedomWitness Evidence Article: Evaluation of Herwenda (trastuzumab biosimilar) by EMA What is established Herwenda is a biosimilar medicine containing trastuzumab, authorised for use in the European Union since November 2023. It is intended to treat HER2-positive cancers, specifically early and metastatic breast cancer and metastatic gastric cancer. The medicine works as a…

Scientific advice for veterinary medicines

Scientific Advice on Veterinary Medicines: An Evidence Overview What is established The European Medicines Agency (EMA) provides scientific advice to companies developing veterinary medicines. This service aims to guide medicine developers on the appropriate tests and studies during the development phase to support marketing authorization applications. The advice is intended to promote…

Understanding vaccines: key scientific terms and platforms

Understanding Vaccines: Key Scientific Terms and Platforms Vaccines remain a cornerstone of public health strategies worldwide. However, understanding them requires familiarity with specific scientific terms and concepts. A report dated November 9, 2026, from a European regulatory agency provides an overview aimed at clarifying the science behind vaccines, their various technological platforms,…

Mandate, objectives, and rules of procedure for working parties under the quality, non-clinical, methodology, clinical and veterinary domains

Mandate and Objectives of EMA Working Parties in Pharmaceutical Domains This dossier reviews information from the European Medicines Agency (EMA) document titled “Mandate, objectives, and rules of procedure for working parties under the quality, non-clinical, methodology, clinical and veterinary domains,” published on November 9, 2026. The document outlines the organizational structure, roles,…

Concerns raised over older heavy drinkers

What is established Recent public health data from the Centers for Disease Control and Prevention (CDC) indicates that alcohol consumption patterns in the United States have shifted notably in the years following the COVID-19 pandemic. While younger adults have shown a decline in drinking rates, a contrasting trend appears among older adults,…

Human medicines European public assessment report (EPAR): Aldurazyme, laronidase, Date of authorisation: 09/06/2003, Revision: 28, Status: Authorised

What is established Aldurazyme is a medicinal enzyme replacement therapy containing the active substance laronidase. It is approved in the European Union for the treatment of mucopolysaccharidosis I (MPS I), a rare inherited metabolic disorder caused by a deficiency in the enzyme ?-L iduronidase. In patients with MPS I, this enzymatic deficiency…

Human medicines European public assessment report (EPAR): Yorvipath, palopegteriparatide, Date of authorisation: 17/11/2023, Revision: 6, Status: Authorised

What is established Yorvipath is a hormone replacement therapy authorized by the European Medicines Agency (EMA) for treating adults with chronic hypoparathyroidism, a rare endocrine disorder characterized by insufficient production of parathyroid hormone (PTH). The active substance in Yorvipath is palopegteriparatide, which the body converts into teriparatide— a shorter form of PTH.…

Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 12, Status: Authorised

Evidence Dossier: Rivaroxaban Viatris – Health & Science What is established Rivaroxaban Viatris is an anticoagulant medication authorized for use in the European Union since November 12, 2021. It contains the active substance rivaroxaban, a direct factor Xa inhibitor, which interferes with thrombin production and helps prevent blood clot formation. The drug…

Human medicines European public assessment report (EPAR): Vabysmo, faricimab, Date of authorisation: 15/09/2022, Revision: 11, Status: Authorised

Evidence Dossier: Vabysmo (faricimab) – Treatment for Retinal Diseases What is established Vabysmo is a medicine containing the active ingredient faricimab, authorized in the European Union since September 15, 2022, for treatment of certain retinal diseases affecting adults. It targets: Wet age-related macular degeneration (wet AMD) — a condition where abnormal blood…